Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced and Incurable Solid Tumors
Lymphoma
Malignant Lymphomas

See also
Status	Clinical Trial	Phase
Completed	`NCT01212341` - Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor	Phase 1
Completed	`NCT01626547` - Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology	N/A
Completed	`NCT01800630` - Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas	Phase 1

See also

Status

Clinical Trial

Phase

Completed

NCT01212341 - Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

Phase 1

Completed

NCT01626547 - Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

N/A

Completed

NCT01800630 - Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01065025
Study type	Interventional
Source	4SC AG
Contact
Status	Completed
Phase	Phase 1
Start date	January 2010
Completion date	April 2015

Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies — AEGIS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms